Stock market today: Nasdaq closes above 23,000 for first time as tech rebounds
Investing.com - Piper Sandler has reiterated its Overweight rating and $115.00 price target on Boston Scientific (NYSE:BSX), a $145.3 billion market cap medical devices company, in a research note released Thursday. According to InvestingPro data, analyst targets for the stock range from $99 to $140, with the company currently trading at a P/E ratio of 58.5x.
The research firm expressed confidence in Boston Scientific’s CHAMPION-AF study, which it views as an important growth driver for the company’s Watchman franchise. Piper Sandler believes the study will likely yield positive results, potentially establishing Watchman as a first-line alternative to drug therapy. The company has demonstrated strong execution, with revenue growing 21.4% in the last twelve months.
While broad adoption would require reimbursement approval, which Piper Sandler estimates could come as early as the first half of 2027, the firm noted that clinical behavior patterns might shift before then.
The research firm projects that Watchman could generate approximately 250 basis points of annual revenue growth for Boston Scientific during the latter half of the decade.
Boston Scientific shares have recently declined due to concerns about third-quarter cardiology results and messaging at an upcoming investor meeting, but Piper Sandler maintains its bullish stance on the stock.
In other recent news, Boston Scientific is capturing attention with several notable developments. Analysts from TD Cowen have reiterated their Buy rating and set a price target of $115, anticipating a long-range plan targeting 10-12% sales growth through 2028. Needham also maintained its Buy rating and $121 price target, highlighting the potential growth from Boston Scientific’s acquisition of Bolt Medical. This acquisition, completed in April 2025, involves plans to launch Bolt’s laser-based intravascular lithotripsy system later this year. Meanwhile, Stifel has focused on Boston Scientific by analyzing electrophysiology hospital purchasing data for the third quarter. This analysis comes as the company prepares for its investor day, where updates on business units and financial targets are expected. Additionally, the Trump administration has launched a Section 232 investigation into medical devices, which could impact the industry, including companies like Boston Scientific. These recent developments have placed Boston Scientific in a prominent position ahead of its investor day.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.